NEU 1.68% $12.91 neuren pharmaceuticals limited

Neuren Media and Analyst Coverage, page-1323

  1. 1,777 Posts.
    lightbulb Created with Sketch. 3113
    Neuren is a commercial property developer.

    Neuren owns trofinetide as commercial property (IP) it has developed.
    Acadia has purchased a lease (licence) on the use of the property to generate income.
    Acadia pays fees to Neuren in accord with the terms of the contracted lease.
    If the terms are not met, use of the property for that purpose reverts back to Neuren.

    Neuren is developing other property for sale or lease.

    At some point the developer may be bought out completely by a larger entity that recognises its income producing value.


    The development and use of intellectual property is very similar to that of real property.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.